A Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: PET imaging analysis, data mining, and AI model developing.
- Who it may be relevant to
- Registry conditions: Lung Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
PET/CT imaging and clinical information (age, gender, smoking history, family history of cancer, history of present illness, and several tumor biomarkers, etc.) were used to establish a hierarchical multi-modal AI framework for pathological and genetic subtyping of lung cancer
Detailed description
The multi-modal AI framework is developed to facilitate a hierarchical and precise stratification process. The first level involves the accurate differentiation between small cell lung cancer and non-small cell lung cancer (NSCLC) in patients diagnosed with lung cancer. The second level entails the further categorization of NSCLC patients into adenocarcinoma, squamous cell carcinoma, and other less prevalent subtypes. The third level involves predicting the mutation status of the EGFR driver gene, which is most-commonly observed in patients with lung adenocarcinoma. The whole cohort was divided into the training cohort (retrospective), validation cohort (retrospective), test cohort (retrospective), and prospective cohort.
Interventions
- Other PET imaging analysis, data mining, and AI model developing
PET imaging analysis, data mining, and AI model developing
Primary outcome measures
- Accurate differentiation between small cell lung cancer and non-small cell lung cancer [Time frame: 1 year]
Secondary outcome measures (1)
- Histological subtyping of NSCLC, including adenocarcinoma, squamous cell carcinoma, and other NSCLC subtypes [Time frame: 1 year]
Eligibility criteria
Inclusion criteria
- Newly diagnosed NSCLC confirmed pathologically
- Age ≥18 y
- Underwent pre-treatment 18F-FDG PET/CT scan
- No prior anti-tumor treatments
- No history of other malignancies
Exclusion criteria
▪ Pure ground-glass nodules with no FDG uptake
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 9 centers
- Guangdong Second Provincial General Hospital — Guangzhou
- Wuhan Tongji Hospital — Wuhan
- Zhongnan Hospital — Wuhan
- Northern Jiangsu People's Hospital — Yangzhou
- First Hospital of China Medical University — Shenyang
- West China Hospital — Chengdu
- The First Affiliated Hospital of Zhejiang Chinese Medical University — Hangzhou
- Department of Nuclear Medicine and PET/CT Center, The Second Affiliated Hospital, School o — Hangzhou
- … and 1 more center
Identifiers
NCT: NCT07463300 · 2024-0689